Loan & DebtMay 18, 2026, 07:16 AM
Gossamer Bio Launches Exchange Offer to Cut Debt by $128M
AI Summary
Gossamer Bio commenced an exchange offer and consent solicitation for its 5.00% Convertible Senior Notes due 2027, aiming to reduce outstanding convertible debt by $128 million to $72 million and extend maturity to 2030. The company also reported a Q1 2026 net loss of $46.7 million, with cash, cash equivalents, and marketable securities totaling $99.2 million as of March 31, 2026, expected to fund operations into Q1 2027. Additionally, Gossamer Bio announced positive PROSERA CT FRI substudy results for seralutinib in PAH and confirmed an in-person Pre-NDA Type B meeting with the FDA in mid-June, with an NDA submission expected in September 2026.
Key Highlights
- Launched exchange offer to reduce outstanding convertible debt by $128M.
- Existing $200M 5.00% Convertible Senior Notes due 2027.
- New 7.50% Convertible Senior Secured First Lien Notes due 2030.
- Holders of approximately 75.2% of existing notes support the exchange offer.
- FDA Pre-NDA Type B meeting for seralutinib in mid-June.
- NDA submission for seralutinib in PAH expected in September 2026.
- Q1 2026 net loss of $46.7M, compared to $36.6M in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $99.2M as of March 31, 2026.
Price Impact
More from GOSS